Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100
About Adare PharmaceuticalsAdare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health. We have expertise in overcoming complex formulation challenges and adding valuable IP to new and existing products—resulting in medicines that deliver greater value to all stakeholders, while meeting the needs of patients. We have the ability to transform drug formulations using our proprietary technologies, developing novel Rx and OTC products. Adare is uniquely suited to unlock the potential of more medicines, helping patients to maximize the benefit of their treatments. We are committed to partnering with innovators in the pharmaceutical industry. Visit www.AdarePharma.com and experience a partnership that's truly transformative.
56 articles with Adare Pharmaceuticals
Adare Pharmaceuticals, Inc. announced that it has entered into an agreement with Egalet Corporation, to acquire global rights of the “ParvuletTM” technology platform and its associated Intellectual Property.
Lannett And Adare Enter Into Distribution Agreement For Dexmethylphenidate Hydrochloride Extended Release Capsules
Lannett Company, Inc. today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride Extended Release (ER) Capsules USP (CII), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg. Lannett expects to commence marketing within a few months.
5/13/2018Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.
Robert J. Rush appointed Vice President, Finance and Chief Financial Officer; Ajay Damani appointed Vice President, Business Unit Leader – Pharmaceutical Technologies; Giuseppe Di Vincenzo named Vice President, Strategy
Adare Pharma Appoints Dr. Peter Richardson As Vice President, Research & Development And Chief Medical Officer
TPG Completes Acquisition of Aptalis Pharmaceutical Technologies, Company Renamed Adare Pharmaceuticals
Forest Laboratories, Inc. Sets $1.8 Billion High Yield Bond Deal To Back Aptalis Pharmaceutical Technologies Buy
Novamedica Signs Distribution Agreement With Aptalis Pharmaceutical Technologies To Develop And Commercialize Gastrointestinal Pharmaceutical Products In Russia
Specialty Drugmaker Aptalis Pharmaceutical Technologies Carries a Hefty $3 Billion Price Tag, Any Takers?
Aptalis Pharmaceutical Technologies Co-Sponsors 2013 Controlled Release Society's Young Investigator Award at 40th Annual Meeting and Exposition
Aptalis Pharmaceutical Technologies Launches PYLERA® in France: A Therapeutic Alternative for Eradicating Helicobacter Pylori and Preventing Relapse of H. Pylori Associated Peptic Ulcers
Aptalis Pharmaceutical Technologies Announces Results of Phase 3 Studies of Aeroquin (Levofloxacin Solution for Inhalation) Among Patients With Cystic Fibrosis and Chronic Lung Infection
Aptalis Pharmaceutical Technologies Announces European Commission Approval for a New Oral Granule Formulation of Viread®